India, Oct. 13 -- Rona Therapeutics has entered into a global licensing agreement with Roche (RHHBY) for an investigational RNA interface (RNAi) therapy targeting activin receptor-like kinase 7 (ALK7), a genetically validated target for obesity and metabolic diseases.
Obesity is a chronic disease associated with a higher risk of diabetes, heart disease and other metabolic conditions. While current treatments often focus on reducing appetite, researchers are also exploring therapies that directly target fat tissue biology.
The licensed therapy targets ALK7, a protein primarily expressed in adipose tissue, or body fat. According to the companies, inhibiting ALK7 has the potential to reduce visceral and other ectopic fat deposits while prese...